These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38754163)

  • 21. RyR2 inhibition with dantrolene is antiarrhythmic, prevents further pathological remodeling, and improves cardiac function in chronic ischemic heart disease.
    Schmeckpeper J; Kim K; George SA; Blackwell DJ; Brennan JA; Efimov IR; Knollmann BC
    J Mol Cell Cardiol; 2023 Aug; 181():67-78. PubMed ID: 37285929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutation-specific differences in arrhythmias and drug responses in CPVT patients: simultaneous patch clamp and video imaging of iPSC derived cardiomyocytes.
    Pölönen RP; Swan H; Aalto-Setälä K
    Mol Biol Rep; 2020 Feb; 47(2):1067-1077. PubMed ID: 31786768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs.
    Li N; Wang Q; Sibrian-Vazquez M; Klipp RC; Reynolds JO; Word TA; Scott L; Salama G; Strongin RM; Abramson JJ; Wehrens XHT
    Int J Cardiol; 2017 Jan; 227():668-673. PubMed ID: 27838126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced binding of calmodulin to RyR2 corrects arrhythmogenic channel disorder in CPVT-associated myocytes.
    Fukuda M; Yamamoto T; Nishimura S; Kato T; Murakami W; Hino A; Ono M; Tateishi H; Oda T; Okuda S; Kobayashi S; Koseki N; Kyushiki H; Yano M
    Biochem Biophys Res Commun; 2014 May; 448(1):1-7. PubMed ID: 24755079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secretoneurin Is an Endogenous Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor That Attenuates Ca
    Ottesen AH; Carlson CR; Eken OS; Sadredini M; Myhre PL; Shen X; Dalhus B; Laver DR; Lunde PK; Kurola J; Lunde M; Hoff JE; Godang K; Sjaastad I; Pettilä V; Stridsberg M; Lehnart SE; Edwards AG; Lunde IG; Omland T; Stokke MK; Christensen G; Røsjø H; Louch WE
    Circ Arrhythm Electrophysiol; 2019 Apr; 12(4):e007045. PubMed ID: 30943765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery and Structure-Activity Relationship of a Ryanodine Receptor 2 Inhibitor.
    Ishida R; Zeng X; Kurebayashi N; Murayama T; Mori S; Kagechika H
    Chem Pharm Bull (Tokyo); 2024; 72(4):399-407. PubMed ID: 38644198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Flecainide Paradoxically Activates Cardiac Ryanodine Receptor Channels under Low Activity Conditions: A Potential Pro-Arrhythmic Action.
    Salvage SC; Gallant EM; Fraser JA; Huang CL; Dulhunty AF
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia.
    Cerrone M; Noujaim SF; Tolkacheva EG; Talkachou A; O'Connell R; Berenfeld O; Anumonwo J; Pandit SV; Vikstrom K; Napolitano C; Priori SG; Jalife J
    Circ Res; 2007 Nov; 101(10):1039-48. PubMed ID: 17872467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+/-) mice with catecholaminergic polymorphic ventricular tachycardia.
    Liu N; Ruan Y; Denegri M; Bachetti T; Li Y; Colombi B; Napolitano C; Coetzee WA; Priori SG
    J Mol Cell Cardiol; 2011 Jan; 50(1):214-22. PubMed ID: 20937285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dantrolene rescues aberrant N-terminus intersubunit interactions in mutant pro-arrhythmic cardiac ryanodine receptors.
    Seidel M; Thomas NL; Williams AJ; Lai FA; Zissimopoulos S
    Cardiovasc Res; 2015 Jan; 105(1):118-28. PubMed ID: 25411383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aging Disrupts Normal Time-of-Day Variation in Cardiac Electrophysiology.
    Wang Z; Tapa S; Francis Stuart SD; Wang L; Bossuyt J; Delisle BP; Ripplinger CM
    Circ Arrhythm Electrophysiol; 2020 Sep; 13(9):e008093. PubMed ID: 32706628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia.
    Di Pasquale E; Lodola F; Miragoli M; Denegri M; Avelino-Cruz JE; Buonocore M; Nakahama H; Portararo P; Bloise R; Napolitano C; Condorelli G; Priori SG
    Cell Death Dis; 2013 Oct; 4(10):e843. PubMed ID: 24113177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity.
    Liu N; Denegri M; Ruan Y; Avelino-Cruz JE; Perissi A; Negri S; Napolitano C; Coetzee WA; Boyden PA; Priori SG
    Circ Res; 2011 Jul; 109(3):291-5. PubMed ID: 21680895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Liu B; Walton SD; Ho HT; Belevych AE; Tikunova SB; Bonilla I; Shettigar V; Knollmann BC; Priori SG; Volpe P; Radwański PB; Davis JP; Györke S
    J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29720499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ryanodine receptor inhibition with acute dantrolene treatment reduces arrhythmia susceptibility in human hearts.
    George SA; Brennan-McLean JA; Trampel KA; Rytkin E; Faye NR; Knollmann BC; Efimov IR
    Am J Physiol Heart Circ Physiol; 2023 Oct; 325(4):H720-H728. PubMed ID: 37566110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accentuated vagal antagonism paradoxically increases ryanodine receptor calcium leak in long-term exercised Calsequestrin2 knockout mice.
    Ho HT; Thambidorai S; Knollmann BC; Billman GE; Györke S; Kalyanasundaram A
    Heart Rhythm; 2018 Mar; 15(3):430-441. PubMed ID: 29030236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Slowed depolarization and irregular repolarization in catecholaminergic polymorphic ventricular tachycardia: a study from cellular Ca2+ transients and action potentials to clinical monophasic action potentials and electrocardiography.
    Paavola J; Väänänen H; Larsson K; Penttinen K; Toivonen L; Kontula K; Laine M; Aalto-Setälä K; Swan H; Viitasalo M
    Europace; 2016 Oct; 18(10):1599-1607. PubMed ID: 26705554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased Ca2+ sensitivity of the ryanodine receptor mutant RyR2R4496C underlies catecholaminergic polymorphic ventricular tachycardia.
    Fernández-Velasco M; Rueda A; Rizzi N; Benitah JP; Colombi B; Napolitano C; Priori SG; Richard S; Gómez AM
    Circ Res; 2009 Jan; 104(2):201-9, 12p following 209. PubMed ID: 19096022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.
    Alcalai R; Wakimoto H; Arad M; Planer D; Konno T; Wang L; Seidman JG; Seidman CE; Berul CI
    J Cardiovasc Electrophysiol; 2011 Mar; 22(3):316-24. PubMed ID: 20807279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterogeneity of ryanodine receptor dysfunction in a mouse model of catecholaminergic polymorphic ventricular tachycardia.
    Loaiza R; Benkusky NA; Powers PP; Hacker T; Noujaim S; Ackerman MJ; Jalife J; Valdivia HH
    Circ Res; 2013 Jan; 112(2):298-308. PubMed ID: 23152493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.